Biodexa Pharmaceuticals Plc (NASDAQ:BDRX – Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 189,600 shares, an increase of 183.8% from the March 31st total of 66,800 shares. Based on an average daily trading volume, of 2,030,000 shares, the days-to-cover ratio is currently 0.1 days.
Wall Street Analyst Weigh In
Separately, LADENBURG THALM/SH SH started coverage on Biodexa Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $8.00 target price on the stock.
Get Our Latest Stock Analysis on Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Price Performance
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.
See Also
- Five stocks we like better than Biodexa Pharmaceuticals
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 4/22 – 4/26
- What is Put Option Volume?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is a Secondary Public Offering? What Investors Need to Know
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.